DC
ABMD

Davenport & Co’s Abiomed Inc ABMD Stock Holding History

Davenport & Co’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-712
Closed -$207K – 722
2018
Q1 		$207K Buy
+712
New +$180K ﹤0.01% 639
2014
Q3 		– Sell
-8,300
Closed -$209K – 623
2014
Q2 		$209K Sell
8,300
-7,100
-46% -$165K ﹤0.01% 542
2014
Q1 		$401K Buy
+15,400
New +$426K 0.01% 403

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Davenport & Co's ABMD Position: Q2 2018 in Review

Davenport & Co sold out of Abiomed Inc (ABMD) in Q2 2018, closing a stake of 712 shares — an estimated $207K sold.

Davenport & Co first reported a position in ABMD in Q1 2014 and held it in 3 quarters. The position peaked at $401K in Q1 2014. 527 funds tracked by Wall St. Rank hold ABMD as of Q2 2018.

  • Davenport & Co reported no remaining Abiomed Inc position as of Q2 2018 after selling out during the quarter.
  • Davenport & Co sold 712 Abiomed Inc shares in Q2 2018, an estimated $207K.
  • Davenport & Co first reported a position in Abiomed Inc in Q1 2014 and held it in 3 quarters.
  • Davenport & Co's Abiomed Inc position peaked at $401K in Q1 2014.
  • 527 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2018.

Based on Davenport & Co's 13F filing for Q2 2018, filed 9 Jul 2018.